metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Infección oculta por el virus de la hepatitis C
Journal Information
Vol. 29. Issue S3.
Programa Externo de Control de Calidad SEIMC. Año 2009
Pages 14-19 (March 2011)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Programa Externo de Control de Calidad SEIMC. Año 2009
Pages 14-19 (March 2011)
Full text access
Infección oculta por el virus de la hepatitis C
Occult hepatitis C virus infection
Visits
5399
Vicente Carreño García
Corresponding author
fehvhpa@fehv.org

Autor para correspondencia.
, Javier Bartolomé Nebreda, Inmaculada Castillo Aguilar, Juan Antonio Quiroga Estévez
Fundación para el Estudio de las Hepatitis Virales, Madrid, España
This item has received
Article information
Resumen

La infección oculta por el virus de la hepatitis C (VHC) se caracteriza por la detección del ARN-VHC en hígado en ausencia de anti-VHC y de ARN-VHC en suero determinados mediante técnicas convencionales. El desarrollo de un nuevo EIA para la detección de anticuerpos frente a un epítopo conservado de la proteína core del VHC junto con la determinación del ARN-VHC en células mononucleares de sangre periférica y en suero tras concentrar las partículas virales mediante ultracentrifugación, permite diagnosticar a más del 90% de los pacientes con infección oculta por VHC sin necesidad de realizar una biopsia hepática. El daño histológico causado por la infección oculta por VHC comprende desde cambios mínimos hasta cirrosis y carcinoma hepatocelular, aunque en general es una enfermedad más benigna que la hepatitis crónica C clásica. Se ha detectado una prevalencia significativa de infección oculta por VHC en grupos de riesgo como pacientes en hemodiálisis y familiares de pacientes diagnosticados de hepatitis C oculta. Además, esta infección oculta puede darse en sujetos sin evidencias clínicas ni bioquímicas de enfermedad hepática.

Palabras clave:
Infección oculta
ARN-VHC
Anti-core VHC
CMSP
Abstract

Occult hepatitis C virus (HCV) infection is characterized by the detection of HCV-RNA in liver in the absence of anti-HCV and serum HCV-RNA determined by conventional techniques. The development of a new enzyme immunoassay for the detection of antibodies against a conserved epitope in the HCV core protein, together with the detection of HCV-RNA in peripheral blood mononuclear cells and in serum after concentrating the viral particles by ultracentrifugation, allow diagnosis of more than 90% of patients with occult HCV without the need to perform a liver biopsy. Histological damage in occult HCV infection ranges from minimal changes to liver cirrhosis and hepatocellular carcinoma, although in general this disease is less severe than classical chronic hepatitis C. A significant prevalence of occult HCV infection has been identified in risk groups such as hemodialysis patients and the family members of patients with occult hepatitis C. This occult HCV infection can also be found in subjects without clinical or biochemical evidence of liver disease.

Keywords:
Occult infection
HCV-RNA
Anti-core HCV
PBMC
Full text is only aviable in PDF
Bibliografía
[1.]
R. Bartenschlager, V. Lohmann.
Replication of hepatitis C virus.
J Gen Virol, 81 (2000), pp. 1631-1648
[2.]
M.G. Ghany, D.B. Strader, D.L. Thomas, L.B. Seef.
Diagnosis, management, and treatment of hepatitis C: an update.
Hepatology, 49 (2009), pp. 1335-1374
[3.]
A. Takaki, M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, et al.
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.
Nat Med, 6 (2000), pp. 578-582
[4.]
L.A. Kondili, P. Chionne, A. Costantino, U. Villano, C. Lo Noce, F. Pannozzo, et al.
Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population.
Gut, 50 (2002), pp. 693-696
[5.]
J.J. Lefrère, R. Girot, F. Lefrère, N. Guillaume, J. Lerable, N. Le Marrec, et al.
Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion.
Transfussion, 44 (2004), pp. 343-348
[6.]
V. Carreño, M. Pardo, J.M. López-Alcorocho, E. Rodríguez-Iñigo, J. Bartolomé, I. Castillo.
Detection of hepatitis C virus (HCV) RNA in the liver of healthy anti-HCV antibody-positive, serum HCV-RNA negative patients with normal alanine aminotransferase levels.
J Infect Dis, 194 (2006), pp. 53-60
[7.]
I. Castillo, M. Pardo, J. Bartolomé, N. Ortíz-Movilla, E. Rodríguez-Iñigo, S. De Lucas, et al.
Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown.
J Infect Dis, 189 (2004), pp. 7-14
[8.]
I. Castillo, E. Rodríguez-Iñigo, J. Bartolomé, S. De Lucas, N. Ortíz-Movilla, J.M. López-Alcorocho, et al.
Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection.
[9.]
V. Falcón, N. Acosta-Rivero, M. Shibayama, J. Luna-Muñoz, M. Miranda-Sánchez, J. Gavilondo, et al.
Evidences of hepatitis C virus replication in hepatocytes and peripheral blood mononuclear cells from patients negative for viral RNA in serum.
Am J Infect Dis, 1 (2005), pp. 34-42
[10.]
M. Radkowski, A. Horban, J.F. Gallegos-Orozco, A. Pawelczyk, J. Jablonska, J. Wilkinson, et al.
Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels.
J Infect Dis, 15 (2005), pp. 1730-1733
[11.]
T.N. Pham, S.A. MacParland, P.M. Mulrooney, H. Cooksley, N.V. Naoumov, T.I. Michalak.
Hepatitis C virus persistence after spontaneous or treatment induced resolution of hepatitis C.
[12.]
M. Radkowski, J.F. Gallegos-Orozco, J. Jablonska, T.V. Colby, B. Walewska-Zielecka, J. Kubicka, et al.
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Hepatology, 41 (2005), pp. 106-114
[13.]
I. Castillo, E. Rodríguez-Iñigo, J.M. López-Alcorocho, M. Pardo, J. Bartolomé, V. Carreño.
Hepatitis C virus replicates in the liver of sustained responder patients to antiviral treatment.
Clin Infect Dis, 43 (2006), pp. 1277-1283
[14.]
V. Carreño, I. Castillo, J. Bartolomé, E. Rodríguez-Iñigo, N. Ortiz-Movilla, S. De Lucas, et al.
Comparison of hepatitis C virus RNA detection in plasma, whole-blood and peripheral blood mononuclear cells of patients with occult hepatitis C virus infection.
J Clin Virol, 31 (2004), pp. 312-313
[15.]
T. Esaki, N. Suzuki, K. Yokoyama, K. Iwata, M. Irie, A. Anan, et al.
Hepatocellular carcinoma in a patient with liver cirrhosis associated with negative serum HCV test but positive liver tissue HCV-RNA.
Intern Med, 43 (2004), pp. 279-282
[16.]
M. Comar, G. Dal Molin, P. D’Agaro, S.L. Croce, C. Tribelli, C. Campillo.
HBV, HCV and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers.
J Clin Pathol, 59 (2006), pp. 526-529
[17.]
H. Zaghloul, W. El-Sherbiny.
Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells.
Immunol Invest, 39 (2010), pp. 284-291
[18.]
L. De Marco, A. Gillio-Tos, V. Fiano, G. Ronco, V. Krogh, D. Palli, et al.
Occult HCV infection: an unexpected finding in a population unselected for hepatic disease.
[19.]
P. Halfon, M. Bourlière, D. Ouzan, D. Sène, D. Saadoun, H. Khiri, et al.
Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay.
J Clin Microbiol, 46 (2008), pp. 2106-2108
[20.]
A. Madejón, M.L. Manzano, C. Arocena, I. Castillo, V. Carreño.
Effects of delayed freezing of liver biopsies on the detection of hepatitis C virus RNA strands.
J Hepatol, 32 (2000), pp. 1019-1025
[21.]
J. Bartolomé, López-Alcorocho, I. Castillo, E. Rodríguez-Iñigo, J.A. Quiroga, R. Palacios, et al.
Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C.
J Virol, 81 (2007), pp. 7710-7715
[22.]
J.T. Stapleton, W.N. Schmidt, L. Katz.
Seronegative hepatitis C virus infection, not just RNA detection.
J Infect Dis, 190 (2004), pp. 651-652
[23.]
J.A. Quiroga, S. Llorente, I. Castillo, E. Rodríguez-Iñigo, M. Pardo, V. Carreño.
Cellular immune responses associated with occult hepatitis C virus infection of the liver.
J Virol, 80 (2006), pp. 10972-10979
[24.]
J.A. Quiroga, I. Castillo, M. Pardo, E. Rodríguez-Iñigo, V. Carreño.
Combined hepatitis C virus (HCV) antigen-antibody detection assay does not improve diagnosis for seronegative individuals with occult HCV infection.
J Clin Microbiol, 44 (2006), pp. 4559-4560
[25.]
J.J. Post, Y. Pan, A.J. Freeman, C.E. Harvey, P.A. White, P. Palladinetti, et al.
Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.
J Infect Dis, 189 (2004), pp. 1846-1855
[26.]
N. Semmo, E. Barnes, C. Taylor, J. Kurtz, G. Harcourt, N. Smith, et al.
T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors.
[27.]
J.M. Echevarría, A. Avellón, G. Jonas, M. Hausmann, A. Vockel, H.P. Kapprell.
Sensitivity of a modified version of the ARCHITECT Anti-HCV test in detecting samples with immunoblot-confirmed, low-level antibody to hepatitis C virus.
J Clin Virol, 35 (2006), pp. 368-372
[28.]
G. Maertens, F. Dekeyser, A. Van Geel, E. Sablon, F. Bosmans, M. Zrein, et al.
Confirmation of HCV antibodies by the Line Immunoassay INNO-LIA™ HCV Ab III update.
pp. 11-26
[29.]
J.A. Quiroga, I. Castillo, S. Llorente, J. Bartolomé, G. Barril, V. Carreño.
Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope.
J Hepatol, 50 (2009), pp. 256-263
[30.]
T.I. Michalak, T.N. Pham.
Anti-HCV core antibody: a potential new marker of occult and otherwise serologically silent HCV infection.
J Hepatol, 50 (2009), pp. 244-246
[31.]
Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol. En prensa 2010.
[32.]
M. Pardo, J.M. López-Alcorocho, E. Rodríguez-Iñigo, I. Castillo, V. Carreño.
Comparative study between occult hepatitis C virus infection and chronic hepatitis C.
J Viral Hepat, 14 (2007), pp. 36-40
[33.]
M. Pardo, J.M. López-Alcorocho, I. Castillo, E. Rodríguez-Iñigo, A. Pérez-Mota, V. Carreño.
Effect of anti-viral therapy for occult hepatitis C virus infection.
Aliment Pharmacol Ther, 23 (2006), pp. 1153-1159
[34.]
G. Barril, I. Castillo, M.D. Arenas, M. Espinosa, J. García-Valdecasas, N. García-Fernández, et al.
Occult hepatitis C virus infection among hemodialysis patients.
J Am Soc Nephrol, 19 (2008), pp. 2288-2292
[35.]
V. Gudagnino, T. Stroffolini, A. Foca, B. Caroleo, L. Loiacono, A. Giancotti, et al.
Hepatitis C virus infection in family setting.
Eur J Epidemiol, 14 (1998), pp. 229-232
[36.]
Z. Ackerman, E. Ackerman, O. Paltiel.
Intrafamilial transmission of hepatitis C virus: a systematic review.
J Viral Hepat, 7 (2000), pp. 93-103
[37.]
I. Castillo, J. Bartolomé, J.A. Quiroga, G. Barril, V. Carreño.
Hepatitis C virus infection in the family setting of patients with occult hepatitis C.
J Med Virol, 81 (2009), pp. 1198-1203
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos